Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, anticipates multiple clinical trial milestones in 2024.
The company's lead drug candidate is UX143 (setrusumab), a monoclonal antibody, for the treatment of Osteogenesis Imperfecta, commonly referred to as brittle bone disease, a hereditary bone condition.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com